Biotech Mailbag 2008 Review

Stock quotes in this article: GILD , ELN , VNDA , AMGN , CEGE , DCTH , GNVC  

A Mailbag review column wouldn't be complete without a mention of Introgen Therapeutics(INGN.PK Quote), which provided much comedic and instructional fodder for how to avoid bad biotech investments. Introgen is now in bankruptcy, alas, so the Mailbag will have to find new biotech stocks to kick around.

Biotech loves controversy, and so does the Mailbag, so in 2009, I hope to continue to answer your questions, absorb your criticisms and savor your praise. More than anything, I hope the Mailbag helps to make some sense out of biotech investing. Thanks again for all your emails this year, and my apologies for the many emails I couldn't find time to answer. I'll try to get to as many of them as possible in 2009.

Happy New Year and, please, keep those emails coming.

  • Loading Comments...
  •  
1 2 3
Next >

SHARE:

  • email
  • print
  • comment
  • digg
  • delicious
  • linkedin
At the time of publication, Feuerstein's Biotech Select model portfolio was long Gilead Sciences and Genentech.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.





Connect with TheStreet

Dow Jones S&P 500 NASDAQ 10-Year Note
10,197.47 1,087.24 2,149.02 34.46
Oil *
76.15
DOWN
93.79
DOWN
11.27
DOWN
17.88
DOWN
0.28
10 Yr
3.45%
SPDR Gold
108.21
-0.91%
-1.03%
-0.83%
-0.81%
Data delayed 20 minutes

Brokerage Partners

TheStreet Premium Services

All Services